Literature DB >> 11819318

Effects of Fuzheng Huayu 319 recipe on liver fibrosis in chronic hepatitis B.

Ping Liu, Cheng Liu, Lie-Ming Xu, Yi-Yang Hu, Hui-Ming Xue, Cheng-Hai Liu, Zhi-Qing Zhang.   

Abstract

AIM:To investigate clinic effects of Fuzheng Huayu 319 recipe (319 recipe) on liver fibrosis in chronic hepatitis B.
METHODS: Ninety-five patients with chronic hepatitis B were divide into the treated (63 cases) and control (32 cases) group, and orally administrated with 0.5g 319 capsule or 0.5g Dahuang Zhachong pill tid for 3 months, respectively. The liver functions and serological fibrotic markers were observed before and after treatment, 12 cases in the treated group were examined with liver biopsy.
RESULTS: Three hundreds nineteen recipe could remarkably decreased serum ALT level and total bilirubin and significantly improve serum albumin and A/G ratio. Its effects were better than Dahuang Zhachong pill. Before treatment, patients'serum monamine oxidase activities, tissue inhibitor of metalloproteinase (TIMP)-1, procollagen type and laminin were all higher than those of health peoples. These levels decreased remarkably after treatment,and urine hydroxyproline level increased significantly (P < 0.001-0.05). Compared with the control, the improvement in treated group was better than that in the control except TIMP-1. According to the scoring system for staging of chronic hepatitis, the fibrotic extents of 7 cases among 12 cases examined by liver biopsy decreased remarkably (1 case decreased by 3 scores, 5 by 2 scores, 1 by 1 score).
CONCLUSION: Fuzheng Huayu 319 recipe had good therapeutic effects on chronic hepatitis B, it could reverse the development of liver fibross to some extent. In general its effects were better than that of Dahuang Zhachong pill.

Entities:  

Year:  1998        PMID: 11819318      PMCID: PMC4761559          DOI: 10.3748/wjg.v4.i4.348

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  6 in total

Review 1.  Classification of chronic hepatitis: diagnosis, grading and staging.

Authors:  V J Desmet; M Gerber; J H Hoofnagle; M Manns; P J Scheuer
Journal:  Hepatology       Date:  1994-06       Impact factor: 17.425

2.  A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues.

Authors:  I S Jamall; V N Finelli; S S Que Hee
Journal:  Anal Biochem       Date:  1981-03-15       Impact factor: 3.365

3.  Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma.

Authors:  Y Murawaki; H Yamamoto; H Kawasaki; H Shima
Journal:  Clin Chim Acta       Date:  1993-09-17       Impact factor: 3.786

4.  Concentration of sodium hyaluronate in serum.

Authors:  A Engström-Laurent; U B Laurent; K Lilja; T C Laurent
Journal:  Scand J Clin Lab Invest       Date:  1985-10       Impact factor: 1.713

5.  Distribution of basement membrane proteins in normal and fibrotic human liver: collagen type IV, laminin, and fibronectin.

Authors:  E Hahn; G Wick; D Pencev; R Timpl
Journal:  Gut       Date:  1980-01       Impact factor: 23.059

6.  Type IV collagen and laminin-related antigens in human serum in alcoholic liver disease.

Authors:  O Niemelä; L Risteli; E A Sotaniemi; J Risteli
Journal:  Eur J Clin Invest       Date:  1985-06       Impact factor: 4.686

  6 in total
  15 in total

1.  Effects of Yigan Decoction on proliferation and apoptosis of hepatic stellate cells.

Authors:  Xi-Xian Yao; You-Wei Tang; Dong-Mei Yao; He-Ming Xiu
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

2.  Expression of RNase H of human hepatitis B virus polymerase in Escherichia coli.

Authors:  Hong Cheng; Hui-Zhong Zhang; Wan-An Shen; Yan-Fang Liu; Fu-Cheng Ma
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

3.  Effect of compound rhodiola sachalinensis A Bor on CCl4-induced liver fibrosis in rats and its probable molecular mechanisms.

Authors:  Xiao-Ling Wu; Wei-Zheng Zeng; Pi-Long Wang; Chun-Tao Lei; Ming-De Jiang; Xiao-Bin Chen; Yong Zhang; Hui Xu; Zhao Wang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

4.  Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4).

Authors:  Hong-Shan Wei; Ding-Guo Li; Han-Ming Lu; Yu-Tao Zhan; Zhi-Rong Wang; Xin Huang; Jing Zhang; Ji-Lin Cheng; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2000-08       Impact factor: 5.742

5.  Effects of drug serum of anti-fibrosis I herbal compound on calcium in hepatic stellate cell and its molecular mechanism.

Authors:  Yong-Hong Xiao; Dian-Wu Liu; Qing Li
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

6.  The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis:effects of RAS inhibitors on hepatic fibrosis induced by CCl(4).

Authors:  Hong-Shan Wei; Han-Ming Lu; Ding-Guo Li; Yu-Tao Zhan; Zhi-Rong Wang; Xin Huang; Ji-Lin Cheng; Qin-Fang Xu
Journal:  World J Gastroenterol       Date:  2000-12       Impact factor: 5.742

7.  Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepatofibrotic rats.

Authors:  L Yao; Z M Yao; T Yu
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

8.  A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes.

Authors:  Ya-Nan Song; Jian Chen; Fei-Fei Cai; Yi-Yu Lu; Qi-Long Chen; Yong-Yu Zhang; Ping Liu; Shi-Bing Su
Journal:  Acta Pharmacol Sin       Date:  2017-10-26       Impact factor: 6.150

9.  Experimental study of effect of Ganyanping on fibrosis in rat livers.

Authors:  Wang-Xian Tang; Zi-Li Dan; Hong-Mei Yan; Cui-Huan Wu; Guo Zhang; Mei Liu; Qin Li; Shao-Bai Li
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

10.  MAPK Signal Transduction Pathway Regulation: A Novel Mechanism of Rat HSC-T6 Cell Apoptosis Induced by FUZHENGHUAYU Tablet.

Authors:  Qi Wang; Hongbo Du; Min Li; Yue Li; Shunai Liu; Ping Gao; Xiaoli Zhang; Jun Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.